blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2640420

EP2640420 - IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.06.2019
Database last updated on 02.11.2024
FormerThe patent has been granted
Status updated on  13.07.2018
FormerGrant of patent is intended
Status updated on  09.07.2018
FormerExamination is in progress
Status updated on  02.07.2018
FormerGrant of patent is intended
Status updated on  20.02.2018
FormerExamination is in progress
Status updated on  26.01.2018
FormerGrant of patent is intended
Status updated on  28.05.2017
FormerExamination is in progress
Status updated on  04.11.2016
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge, MA 02139 / US
[2013/39]
Inventor(s)01 / KANDIMALLA, Ekambar, R.
3 Overlook Road
Hopkinton, MA 01748 / US
02 / WANG, Daqing
7 Selfridge Road
Bedford, MA 01730 / US
03 / NOWAK, Ireneusz
592 Cambridge St., 22
Allston, MA 02134 / US
04 / AGRAWAL, Sudhir
61 Lamplighter Drive
Shrewsbury, MA 01545 / US
 [2018/33]
Former [2013/39]01 / KANDIMALLA, Ekambar, R.
3 Overlook Road
Hopkinton, MA 01748 / US
02 / WANG, Daqing
7 Selfridge Road
Bedford, MA 01730 / US
03 / NOWAK, Ireneusz
592 Cambridge St. 22
Allston, MA 02134 / US
04 / AGRAWAL, Sudhir
61 Lamplighter Drive
Shrewsbury, MA 01545 / US
Representative(s)Schnappauf, Georg
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2018/33]
Former [2013/39]Schnappauf, Georg
Dr. Volker Vossius
Patentanwälte / Partnerschaftsgesellschaft
Radlkoferstrasse 2
81373 München / DE
Application number, filing date11841875.518.11.2011
[2018/33]
WO2011US61412
Priority number, dateUS20100415494P19.11.2010         Original published format: US 415494 P
US201161511709P26.07.2011         Original published format: US 201161511709 P
[2013/39]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012068470
Date:24.05.2012
Language:EN
[2012/21]
Type: A2 Application without search report 
No.:EP2640420
Date:25.09.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 24.05.2012 takes the place of the publication of the European patent application.
[2013/39]
Type: B1 Patent specification 
No.:EP2640420
Date:15.08.2018
Language:EN
[2018/33]
Search report(s)International search report - published on:US12.09.2013
(Supplementary) European search report - dispatched on:EP13.10.2014
ClassificationIPC:C12N15/117, A61K31/7115
[2017/22]
CPC:
C12N15/117 (EP,CN,KR,US); A61K31/7115 (EP,CN,KR,US); A61K31/7125 (EP,KR,US);
A61K45/06 (EP,KR,US); A61P1/00 (EP); A61P1/16 (EP);
A61P11/00 (EP); A61P13/00 (EP); A61P13/10 (EP);
A61P13/12 (EP); A61P15/00 (EP); A61P17/00 (EP);
A61P17/06 (EP,KR); A61P19/02 (EP); A61P19/08 (EP);
A61P21/00 (EP); A61P21/04 (EP); A61P25/00 (EP);
A61P25/18 (EP); A61P29/00 (EP); A61P31/00 (EP);
A61P35/00 (EP); A61P37/02 (EP,KR); A61P37/06 (EP);
A61P43/00 (EP); A61P5/14 (EP); A61P7/04 (EP);
A61P7/06 (EP); A61P9/00 (EP); C12N2310/17 (EP,CN,KR,US);
C12N2310/31 (KR,US); C12N2310/317 (EP,CN,KR,US); C12N2310/321 (EP,KR,US);
C12N2310/3341 (EP,KR,US); C12N2310/336 (EP,KR,US); C12N2310/3521 (EP);
C12N2310/51 (EP,CN,KR,US); C12N2310/52 (EP,CN,KR,US); Y02A50/30 (EP,KR,US) (-)
C-Set:
A61K31/7115, A61K2300/00 (CN,EP,US)
Former IPC [2014/46]A61K48/00, C07H21/04, C12N15/113
Former IPC [2013/45]A61K48/00, C07H21/04
Former IPC [2013/39]A61K39/395, C07H21/02, A61K31/7115, A61K39/00, A61P37/06, A61P17/06, A61P19/02, A61P7/06, A61P11/00, A61P25/00, A61P31/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/39]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:IMMUNREGULATORISCHE OLIGONUKLEOTID (IRO)-VERBINDUNGEN ZUR MODULATION VON IMMUNREAKTIONEN AUF DER BASIS VON TOLL-LIKE-REZEPTOREN[2013/39]
English:IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE[2013/39]
French:COMPOSÉS OLIGONUCLÉOTIDIQUES IMMUNO-RÉGULATEURS (IRO) CAPABLES DE MODULER LA RÉPONSE IMMUNITAIRE FONDÉE SUR LES RÉCEPTEURS DE TYPE TOLL (TLR)[2013/39]
Entry into regional phase07.06.2013National basic fee paid 
07.06.2013Search fee paid 
07.06.2013Designation fee(s) paid 
07.06.2013Examination fee paid 
Examination procedure07.06.2013Examination requested  [2013/39]
30.07.2015Amendment by applicant (claims and/or description)
04.11.2016Despatch of a communication from the examining division (Time limit: M04)
14.02.2017Reply to a communication from the examining division
29.05.2017Communication of intention to grant the patent
14.11.2017Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
22.01.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
21.02.2018Communication of intention to grant the patent
29.06.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
29.06.2018Fee for grant paid
29.06.2018Fee for publishing/printing paid
09.07.2018Information about intention to grant a patent
09.07.2018Receipt of the translation of the claim(s)
Divisional application(s)EP17166068.1  / EP3213770
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.11.2016
Opposition(s)16.05.2019No opposition filed within time limit [2019/30]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
22.01.2018Request for further processing filed
22.01.2018Full payment received (date of receipt of payment)
Request granted
02.02.2018Decision despatched
The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
30.07.2015Request for further processing filed
30.07.2015Full payment received (date of receipt of payment)
Request granted
28.08.2015Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
30.07.2015Request for further processing filed
30.07.2015Full payment received (date of receipt of payment)
Request granted
28.08.2015Decision despatched
Fees paidRenewal fee
27.11.2013Renewal fee patent year 03
26.11.2014Renewal fee patent year 04
30.11.2015Renewal fee patent year 05
28.11.2016Renewal fee patent year 06
27.11.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.11.2011
AL15.08.2018
AT15.08.2018
CY15.08.2018
DK15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
MK15.08.2018
PL15.08.2018
PT15.08.2018
RO15.08.2018
RS15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
TR15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
LU18.11.2018
MT18.11.2018
BE30.11.2018
IS15.12.2018
[2020/31]
Former [2020/30]HU18.11.2011
AL15.08.2018
AT15.08.2018
DK15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
PL15.08.2018
PT15.08.2018
RO15.08.2018
RS15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
TR15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
LU18.11.2018
MT18.11.2018
BE30.11.2018
IS15.12.2018
Former [2020/27]AL15.08.2018
AT15.08.2018
DK15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
PL15.08.2018
PT15.08.2018
RO15.08.2018
RS15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
TR15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
LU18.11.2018
MT18.11.2018
BE30.11.2018
IS15.12.2018
Former [2020/16]AL15.08.2018
AT15.08.2018
DK15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
TR15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
LU18.11.2018
MT18.11.2018
BE30.11.2018
IS15.12.2018
Former [2020/08]AL15.08.2018
AT15.08.2018
DK15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
LU18.11.2018
MT18.11.2018
BE30.11.2018
IS15.12.2018
Former [2019/51]AL15.08.2018
AT15.08.2018
DK15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
LU18.11.2018
BE30.11.2018
IS15.12.2018
Former [2019/37]AL15.08.2018
AT15.08.2018
DK15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SI15.08.2018
SK15.08.2018
SM15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
LU18.11.2018
IS15.12.2018
Former [2019/34]AL15.08.2018
AT15.08.2018
DK15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SK15.08.2018
SM15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
LU18.11.2018
IS15.12.2018
Former [2019/33]AL15.08.2018
AT15.08.2018
DK15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
MC15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SK15.08.2018
SM15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/26]AL15.08.2018
AT15.08.2018
DK15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SK15.08.2018
SM15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/24]AL15.08.2018
AT15.08.2018
EE15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
SK15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/22]AL15.08.2018
AT15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
PL15.08.2018
RO15.08.2018
RS15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/12]AL15.08.2018
AT15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
LV15.08.2018
RS15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/11]AT15.08.2018
FI15.08.2018
HR15.08.2018
LT15.08.2018
RS15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/10]AT15.08.2018
FI15.08.2018
LT15.08.2018
RS15.08.2018
BG15.11.2018
NO15.11.2018
GR16.11.2018
IS15.12.2018
Former [2019/08]FI15.08.2018
LT15.08.2018
NO15.11.2018
IS15.12.2018
Former [2019/07]LT15.08.2018
Documents cited:Search[I]WO2009154609  (IDERA PHARMACEUTICALS INC [US], et al) [I] 1-14 * the whole document *;
 [I]  - DONG YU ET AL., "Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of Toll-like Receptors 7 and 9", JOURNAL OF MEDICINAL CHEMISTRY, (20090827), vol. 52, no. 16, doi:10.1021/jm900730r, ISSN 0022-2623, pages 5108 - 5114, XP055142785 [I] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm900730r
 [A]  - KANDIMALLA E.R. ET AL., "Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships", BIOORGANIC & MEDICINAL CHEMISTRY, (20010301), vol. 9, no. 3, doi:10.1016/S0968-0896(00)00316-3, pages 807 - 813, XP002198015 [A] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0968-0896(00)00316-3
International search[X]US2009060898  (KANDIMALLA EKAMBAR R [US], et al);
 [Y]US2009131512  (BARRAT FRANCK [US], et al)
by applicantUS6426334
 US2004097719
 US2005239733
 US2008089883
 US2009060898
 US2009087388
 WO2009154609
 US8383598
 US8399423
    - HORNUNG, V. ET AL., J. IMMUNOL., (2002), vol. 168, pages 4531 - 4537
    - POLTORAK ET AL., SCIENCE, (1998), vol. 282, pages 2085 - 2088
    - UNDERBILL, D.M. ET AL., NATURE, (1999), vol. 401, pages 811 - 815
    - HAYASHI, F., NATURE, (2001), vol. 410, pages 1099 - 1103
    - ZHANG, D. ET AL., SCIENCE, (2004), vol. 303, pages 1522 - 1526
    - MEIER, A. ET AL., CELL. MICROBIOL., (2003), vol. 5, pages 561 - 570
    - CAMPOS, M.A. ET AL., J. IMMUNOL., (2001), vol. 167, pages 416 - 423
    - HOEBE, K. ET AL., NATURE, (2003), vol. 424, pages 743 - 748
    - LUND, J., J. EXP. MED., (2003), vol. 198, pages 513 - 520
    - HEIL, F. ET AL., SCIENCE, (2004), vol. 303, pages 1526 - 1529
    - DIEBOLD, S.S. ET AL., SCIENCE, (2004), vol. 303, pages 1529 - 1531
    - HORNUNG, V. ET AL., J. IMMUNOL., (2004), vol. 173, pages 5935 - 5943
    - AKIRA, S. ET AL., NATURE IMMUNOL., (2001), vol. 2, pages 675 - 680
    - MEDZHITOV, R., NATURE REV. IMMUNOL., (2001), vol. 1, pages 135 - 145
    - COOK, D.N. ET AL., NATURE IMMUNOL., (2004), vol. 5, pages 975 - 979
    - LIEW, F. ET AL., NATURE, (2005), vol. 5, pages 446 - 458
    - HEMMI H ET AL., NAT IMMUNOL, (2002), vol. 3, pages 196 - 200
    - JURK M ET AL., NAT IMMUNOL, (2002), vol. 3, page 499
    - LEE J ET AL., PROC. NATL. ACAD. SCI. USA, (2003), vol. 100, pages 6646 - 6651
    - ALEXOPOULOU, L., NATURE, (2001), vol. 413, pages 732 - 738
    - TOKUNAGA T ET AL., J. NATL. CANCER INST., (1984), vol. 72, pages 955 - 962
    - SHIMADA S ET AL., JPN. H CANCER RES, (1986), vol. 77, pages 808 - 816
    - YAMAMOTO S ET AL., JPN. J. CANCER RES., (1986), vol. 79, pages 866 - 73
    - ZHAO Q ET AL., BIOCHEM.PHARMACOL., (1996), vol. 26, pages 173 - 182
    - HEMMI, H. ET AL., NATURE, (2000), vol. 408, pages 740 - 745
    - ZHAO ET AL., BIOCHEM. PHARMACOL., (1996), vol. 51, pages 173 - 182
    - ZHAO ET AL., BIOCHEM PHARMACOL., (1996), vol. 52, pages 1537 - 1544
    - ZHAO ET AL., ANTISENSE NUCLEIC ACID DRUG DEV., (1997), vol. 7, pages 495 - 502
    - ZHAO ET AL., BIOORG. MED. CHEM. LETT., (1999), vol. 9, pages 3453 - 3458
    - ZHAO ET AL., BIOORG. MED. CHEM. LETT., (2000), vol. 10, pages 1051 - 1054
    - YU, D. ET AL., BIOORG. MED. CHEM. LETT., (2000), vol. 10, pages 2585 - 2588
    - YU, D. ET AL., BIOORG. MED. CHEM. LETT., (2001), vol. 11, pages 2263 - 2267
    - KANDIMALLA, E. ET AL., BIOORG. MED. CHEM., (2001), vol. 9, pages 807 - 813
    - KANDIMALLA, E. ET AL., PROC. NATL. ACAD. SCI. U S A, (2005), vol. 102, pages 6925 - 6930
    - KANDIMALLA, E. ET AL., PROC. NAT. ACAD. SCI. U S A, (2003), vol. 100, pages 14303 - 14308
    - CONG, Y. ET AL., BIOCHEM BIOPHYS RES. COMMUN., (2003), vol. 310, pages 1133 - 1139
    - KANDIMALLA, E. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (2003), vol. 306, pages 948 - 953
    - KANDIMALLA, E. ET AL., NUCLEIC ACIDS RES., (2003), vol. 31, pages 2393 - 2400
    - YU, D. ET AL., BIOORG. MED. CHEM., (2003), vol. 11, pages 459 - 464
    - BHAGAT, L. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (2003), vol. 300, pages 853 - 861
    - YU, D. ET AL., NUCLEIC ACIDS RES., (2002), vol. 30, pages 4460 - 4469
    - YU, D. ET AL., J. MED. CHEM., (2002), vol. 45, pages 4540 - 4548
    - YU, D. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (2002), vol. 297, pages 83 - 90
    - KANDIMALLA. E. ET AL., BIOCONJUG. CHEM., (2002), vol. 13, pages 966 - 974
    - YU, D. ET AL., NUCLEIC ACIDS RES., (2002), vol. 30, pages 1613 - 1619
    - YU, D. ET AL., BIOORG. MED. CHEM., (2001), vol. 9, pages 2803 - 2808
    - PUTTA, M. ET AL., NUCLEIC ACIDS RES., (2006), vol. 34, pages 3231 - 3238
    - LENERT, P. ET AL., DNA CELL BIOL., (2003), vol. 22, no. 10, pages 621 - 631
    - CHEN, Y. ET AL., GENE THER., (2001), vol. 8, pages 1024 - 1032
    - STUNZ, L.L., EUR. J. IMMUNOL., (2002), vol. 32, pages 1212 - 1222
    - DURAMAD, O. ET AL., J. IMMUNOL., (2005), vol. 174, pages 5193 - 5200
    - PATOLE, P. ET AL., J. AM. SOC. NEPHROL., (2005), vol. 16, pages 3273 - 3280
    - GURSEL, I. ET AL., J. IMMUNOL., (2003), vol. 171, pages 1393 - 1400
    - SHIROTA, H. ET AL., J. IMMUNOL., (2004), vol. 173, pages 5002 - 5007
    - VERTHELYI D ET AL., J IMMUNOL., (2001), vol. 166, page 2372
    - GURSEL M ET AL., J LEUKOC BIOL, (2001), vol. 71, page 813
    - KRUG A ET AL., EUR J IMMUNOL, (2001), vol. 31, page 2154
    - BALLAS GK ET AL., J IMMUNOL, (2001), vol. 167, page 4878
    - VERTHELYI D ET AL., J IMMUNOL, (2003), vol. 170, page 4717
    - MCSHAN WM ET AL., J BIOL CHEM., (1992), vol. 267, no. 8, pages 5712 - 21
    - RANDO, RF ET AL., J BIOL CHEM, (1995), vol. 270, no. 4, pages 1754 - 60
    - BENIMETSKAYA L ET AL., NUCLEIC ACIDS RES., (1997), vol. 25, no. 13, pages 2648 - 56
    - BOCK LC ET AL., NATURE, (1992), vol. 355, pages 564 - 6
    - PADMANABHAN, K ET AL., J BIOL CHEM., (1993), vol. 268, no. 24, pages 17651 - 4
    - UHLMANN E ET AL., CHEM. REV., (1990), vol. 90, page 543
    - HUNZIKER, J. ET AL., MOD. SYN. METHODS, (1995), vol. 7, pages 331 - 417
    - CROOKE, S. ET AL., ANN.REV. PHARM. TOX., (1996), vol. 36, pages 107 - 129
    - NORONHA ET AL., BIOCHEM., (2000), vol. 39, pages 7050 - 7062
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.